Marie-Aude Khuong-Josses

机构：Centre Hospitalier Saint-Denis

发表论文 40 篇 · 总被引 1773 次 · h-index 14

代表论文

• Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study (2020 · The Lancet · 被引 375)
• Brief Report (2015 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 223)
• Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies (2019 · The Lancet HIV · 被引 118)
• Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks (2020 · AIDS and Behavior · 被引 86)
• Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study (2021 · Open Forum Infectious Diseases · 被引 64)
• Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials (2020 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 51)